Vimarsana
Biggest News Aggregation in the World

Same Active News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Same Active. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Same Active Today - Breaking & Trending Today

BeiGene Announces Expansion of Coverage on China's National Reimbursement Drug List - Vimarsana News

BeiGene Announces Expansion of Coverage on China's National Reimbursement Drug List

Four new indications added for tislelizumab and all nine approved indications now included in NRDL KYPROLIS included for the first time XGEVA successfully renewed BeiGene (NASDAQ: BGNE; HKEX:

Amgen To Showcase New Data From Oncology Portfolio At ASCO 2021 - Vimarsana News

Amgen To Showcase New Data From Oncology Portfolio At ASCO 2021

Amgen To Showcase New Data From Oncology Portfolio At ASCO 2021 LUMAKRAS™ (Sotorasib)¹ Overall Survival and Biomarker Subgroup Analyses From Registrational Phase 2 CodeBreaK 100 Trial in KRAS G12C-Mutated Non-Small Cell Lung Cancer New Data From the Phase 2 FIGHT Trial with Bemarituzumab in Advanced Gastric and Gastroesophageal Junction Cancers News provided by Share this article Share this article THOUSAND OAKS, Calif., May 19, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that new data from its expanding oncology pipeline and marketed portfolio will be presented during the 20...

BeiGene Announces Inclusion of Three Innovative Oncology Products in China National Reimbursement Drug List (NRDL) - Press Release - Vimarsana News

BeiGene Announces Inclusion of Three Innovative Oncology Products in China National Reimbursement Drug List (NRDL) - Press Release

®, including anaphylaxis that has been reported with use of XGEVA ®. Reactions may include hypotension, dyspnea, upper airway edema, lip swelling, rash, pruritus, and urticaria. If an anaphylactic or other clinically significant allergic reaction occurs, initiate appropriate therapy and discontinue XGEVA ® therapy permanently. Patients receiving XGEVA ® (denosumab). Osteonecrosis of the jaw (ONJ) has been reported in patients receiving XGEVA ®, manifesting as jaw pain, osteomyelitis, osteitis, bone erosion, tooth or periodontal infection, toothache, gingival ulceration, or gingival erosi...

BeiGene Announces Inclusion of Three Innovative Oncology Products in China National Reimbursement Drug List (NRDL) - Vimarsana News

BeiGene Announces Inclusion of Three Innovative Oncology Products in China National Reimbursement Drug List (NRDL)

®, including anaphylaxis that has been reported with use of XGEVA ®. Reactions may include hypotension, dyspnea, upper airway edema, lip swelling, rash, pruritus, and urticaria. If an anaphylactic or other clinically significant allergic reaction occurs, initiate appropriate therapy and discontinue XGEVA ® therapy permanently. Patients receiving XGEVA ® (denosumab). Osteonecrosis of the jaw (ONJ) has been reported in patients receiving XGEVA ®, manifesting as jaw pain, osteomyelitis, osteitis, bone erosion, tooth or periodontal infection, toothache, gingival ulceration, or gingival erosi...